Associated Papers
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K et al.
Ebiomedicine, 2021
33862582 (PubMed )
Supplement: mmc3.xlsx › S5
CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.
Chan SH et al.
Hereditary Cancer in Clinical Practice, 2021
Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes.
Lu J et al.
Cancer Medicine, 2021
33350171 (PubMed )
Supplement: CAM4-10-933-s001.xlsx › SNV
Select a paper to view details